Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
First Claim
1. A composition for treating or preventing drug induced QT prolongation in a human or animal subject comprising:
- a combination of i) one or more pharmacologically active agents that induce QT prolongation in the subject; and
ii)one or more empty liposomes, wherein the empty liposomes are provided in an amount sufficient to prevent or reduce the QT prolongation caused by the one or more pharmacologically active agents, wherein the combination is dispersed in a pharmaceutically acceptable medium, solvent, or vehicle and wherein said combination of i) and ii) reduces hERG current inhibition as compared to i) alone.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.
-
Citations
14 Claims
-
1. A composition for treating or preventing drug induced QT prolongation in a human or animal subject comprising:
-
a combination of i) one or more pharmacologically active agents that induce QT prolongation in the subject; and
ii)one or more empty liposomes, wherein the empty liposomes are provided in an amount sufficient to prevent or reduce the QT prolongation caused by the one or more pharmacologically active agents, wherein the combination is dispersed in a pharmaceutically acceptable medium, solvent, or vehicle and wherein said combination of i) and ii) reduces hERG current inhibition as compared to i) alone. - View Dependent Claims (2, 3, 4, 5, 6, 7, 13)
-
-
8. A composition for preventing or treating QT prolongation caused by administration of a therapeutically active agent or a drug in a human or animal subject comprising:
-
one or more liposomes in combination with a therapeutically active agent or a drug that causes QT prolongation, wherein the liposomes are empty liposomes in an amount sufficient to prevent or reduce the QT prolongation caused by the therapeutically active agent or the drug; and a pharmaceutically acceptable dispersion medium, solvent, or vehicle, wherein the active agent or drug, the liposome or both are dissolved, dispersed, or suspended in the medium, the solvent, or the vehicle and wherein said combination reduces hERG current inhibition as compared to said active agent or drug alone. - View Dependent Claims (9, 10, 11, 14)
-
-
12. A composition for preventing or treating long QT syndrome (LQTS) arising from administration of Terfenidine, or Methanesulphonanilide (E-4031) in a human or animal subject comprising:
-
i) one or more liposomes, wherein the liposomes are empty liposomes and ii) Terfenidine, or Methanesulphonanilide (E-4031); and a pharmaceutically acceptable dispersion medium, solvent, or vehicle, wherein the Terfenidine, or Methanesulphonanilide (E-4031), and the liposome are dissolved, dispersed, or suspended in the medium, the solvent, or the vehicle.
-
Specification